Review tallies eight mitochondrial-derived peptides with almost no human dosing data
Humanin, MOTS-c and six small humanin-like peptides have been characterized mostly in cell cultures and mice, with human work limited to measuring endogenous levels.
PR
By Priya Raman · Science Reporter
Oct 12 08:25 ETSource: BioPharma APAC
The wire
- 01BioPharma APAC reviews the eight described mitochondrial-derived peptides, noting MOTS-c, a 16-amino-acid peptide from the 12S rRNA region, was first reported in Cell Metabolism in 2015.
- 02Readers tracking longevity peptides get a plain accounting of the evidence base: AMPK activation, improved insulin response and less weight gain in high-fat-diet mice.
- 03The review stresses that administering MDPs to humans has barely been studied, and that identifying a short coding sequence does not establish a functional molecule.
From the source
Read at biopharmaapac.comMitochondrial-Derived Peptides: What Research Has Shown So Far
Scientists have described eight MDPs: humanin, MOTS-c and six small humanin-like peptides (SHLP1 to SHLP6). Research has focused on different aspects of their activity. Humanin has been studied in models of cell injury, MOTS-c in metabolic experiments, and several SHLPs in work involving insulin signaling and cellular stress. Most of this work has been done in cell cultures and animals. In people,
